Medicover AB/Skr MCOV B
1D1W1MYTD1Y5YMAX
Capital at risk
About Medicover AB
Medicover AB is a healthcare company that operates in the medical care and diagnostic services industry. It provides a wide range of healthcare services, including preventive care, specialist consultations, and surgeries, as well as laboratory and diagnostic tests. Founded in 1995, Medicover has developed a significant presence in Central and Eastern Europe, with its headquarters located in Stockholm, Sweden. The company strategically positions itself to offer both insurance services and healthcare services, allowing it to leverage synergies between these segments. It continues to expand its geographic footprint through acquisitions and organic growth, aiming to provide comprehensive healthcare solutions across its markets.
- Ticker
- Skr MCOV B
- Sector
- Health
- Primary listing
- XSTO
- Employees
- 49,000
- Headquarters
- Stockholm, Sweden
- Website
- www.medicover.com
Medicover AB Metrics
BasicAdvanced
kr 37B
39.00
kr 6.33
1.50
kr 2.17
0.88%
Price and volume
Market cap
kr 37B
Beta
1.5
52-week high
kr 267.00
52-week low
kr 179.40
Average daily volume
76K
Dividend rate
kr 2.17
Financial strength
Current ratio
0.55
Quick ratio
0.481
Long term debt to equity
1.559
Total debt to equity
2.642
Dividend payout ratio (TTM)
35.57%
Interest coverage (TTM)
2.71%
Profitability
EBITDA (TTM)
3,152.476
Gross margin (TTM)
23.37%
Net profit margin (TTM)
3.44%
Operating margin (TTM)
7.18%
Effective tax rate (TTM)
26.31%
Revenue per employee (TTM)
kr 564,350
Management effectiveness
Return on assets (TTM)
4.66%
Return on equity (TTM)
15.49%
Valuation
Price to earnings (TTM)
38.995
Price to revenue (TTM)
1.34
Price to book
69.79
Price to tangible book (TTM)
-134.03
Price to free cash flow (TTM)
17.755
Free cash flow yield (TTM)
5.63%
Free cash flow per share (TTM)
13.912
Dividend yield (TTM)
0.88%
Forward dividend yield
0.88%
Growth
Revenue change (TTM)
9.28%
Earnings per share change (TTM)
94.43%
3-year revenue growth (CAGR)
15.29%
3-year earnings per share growth (CAGR)
149.49%
3-year dividend per share growth (CAGR)
18.56%
Bulls say / Bears say
Organic revenue growth reached 11.8% to EUR 640.4 million in Q2 2026, driven by strong demand across core markets. (Medicover Q2 Interim report)
Operating profit (EBIT) rose 22.6% to EUR 51.2 million in Q2 2026, lifting the operating margin to 8.0% from 7.0% year-over-year. (Medicover Q2 Interim report)
Net cash flow from operating activities was EUR 73.6 million in Q2 2026, underpinning robust free cash generation for debt repayment and reinvestment. (Medicover Q2 Interim report)
The net debt to EBITDAaL leverage ratio remained elevated at 2.9x at the end of Q2 2026, approaching covenant thresholds and constraining financial flexibility. (Medicover CEO statement)
Medicover's Indian hospital unit reported only 1% revenue growth in 2025, reflecting stagnation in a key emerging market. (Moneycontrol)
The €1.2 billion sale of the India hospital business to KKR reduces exposure to one of the fastest-growing healthcare markets, potentially slowing long-term top-line expansion. (Yahoo Finance)
Data summarised monthly by Lightyear AI. Last updated on 30 Aug 2026.
Upcoming events
No upcoming events
Funds containing Medicover AB
AllEURGBPUSD
Fund name | Fund size | Skr MCOV B weighting |
|---|---|---|
iShares Ageing Population€AGED | €822M | 0.16% |
Xtrackers MSCI Europe Small Cap€DX2J | €3.2B | 0.11% |
Xtrackers MSCI Europe Small Cap£XXSC | £2.8B | 0.11% |
iShares MSCI World Small Cap$WSML | $9B | 0.02% |
iShares MSCI World Small Cap€IUSN | €7.8B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.